Originally published by our sister publication Pain Medicine News
The FDA announced its final guidance on clinical research with cannabis that includes clarifying sources of cannabis for clinical research (including Schedule I sources), additional resources detailing expectations for Investigational New Drug (IND) applications in different stages of drug development and guidance on quality considerations for INDs, as well as considerations of control status under the Controlled Substances Act